SHIELD THERAPEUTICS PLC (LON:STX)

Founded in 2008, Shield Therapeutics plc is a UK-based commercial stage specialty pharmaceutical company that aims to offer innovative specialty pharmaceuticals to address significant unmet needs in the treatment of hyperphosphatemia and iron deficiency. It primary goal is the development and commercialization of its lead product Feraccru/Accrufer, a novel oral therapy for the treatment of iron deficiency (ID) with or without anaemia in adult that is approved in European Union, United States, UK and Switzerland. The company’s shares are listed on the Alternative Investment Market (AIM) segment of the London Stock Exchange as LON: STX since 2016.

The company has a licence agreement with ASK Pharma, who will help in the development and commercialization in Taiwan, China, Macau and Hong Kong. In Europe its Feraccru product is sold with commercialisation led by Norgine BV and in US as Accrufer.  The company’s product portfolio includes Feraccru/Accrufer and PT20. The company’s lead product, Feraccru/Accrufer, which is a stable, non-salt based oral therapy for adults with iron deficiency and it has a novel mechanism of absorption compared to other oral therapies. It is currently in an active comparator phase three clinical trials and has been an effective and well-tolerated therapy in a range of placebo-controlled. It has exclusive IP rights until the mid 2030s. The company’s PT20 product is licensed by United Kingdom Research and Innovation in UK, which is a novel iron-based phosphate binder that is used to treat patients with hyperphosphosphatemia related to dialysis or non-dialysis dependent chronic kidney disease (CKD). The PT20 patent is protected till 2029 and five year supplementary protection is expected to be provided upon approval in Europe, which will extend the patent till 2034 same as US. For marketing approval PT20 need to complete its second pivotal study.